Structural neuroimaging in Alzheimer's disease: do white matter hyperintensities matter? by Brickman, Adam M. et al.
ith advancing age comes inevitable decline in
most biological systems. Perhaps among the most dev-
astating is the targeted brain dysfunction that accom-
panies aging, and its negative impact on cognitive and
intellectual abilities. Descriptively, cognitive aging
across individuals is heterogeneous. Some experience
a precipitous and universal decline in cognitive abili-
ties, while others experience more subtle downward
cognitive trajectories in certain cognitive domains, with
preservation or even improvement in others. From a
taxonomic perspective, when age-associated cognitive
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The targeted brain dysfunction that accompanies aging can have a devastating effect on cognitive and intellectual
abilities. A significant proportion of older adults experience precipitous cognitive decline that negatively impacts func-
tional activities. Such individuals meet clinical diagnostic criteria for dementia, which is commonly attributed to
Alzheimer’s disease (AD). Structural neuroimaging, including magnetic resonance imaging (MRI), has contributed sig-
nificantly to our understanding of the morphological and pathology-related changes that may underlie normal and
disease-associated cognitive change in aging. White matter hyperintensities (WMH), which are distributed patches of
increased hyperintense signal on T2-weighted MRI, are among the most common structural neuroimaging findings in
older adults. In recent years, WMH have emerged as robust radiological correlates of cognitive decline. Studies sug-
gest that WMH distributed in anterior brain regions are related to decline in executive abilities that is typical of nor-
mal aging, whereas WMH distributed in more posterior brain regions are common in AD. Although epidemiologi-
cal, observational, and pathological studies suggest that WMH may be ischemic in origin and caused by consistent
or variable hypoperfusion, there is emerging evidence that they may also reflect vascular deposition of -amyloid, par-
ticularly when they are distributed in posterior areas and are present in patients with AD. Findings from the literature
highlight the potential contribution of small-vessel cerebrovascular disease to the pathogenesis of AD, and suggest a
mechanistic interaction, but future longitudinal studies using multiple imaging modalities are required to fully under-
stand the complex role of WMH in AD. 
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we define the syndrome as “dementia” and assign the
most likely etiology. By far, probable Alzheimer’s dis-
ease (AD) is the most commonly diagnosed cause of
dementia. Other commonly diagnosed causes include
dementia due to cerebrovascular disease (ie, “vascular
dementia”) and dementia due to Lewy bodies. The con-
cept of mild cognitive impairment (MCI) first gained
popularity in the 1990s to categorize older adults who
evidence some degree of cognitive decline but not
enough to impact functional abilities and meet formal
criteria for dementia. Mild cognitive impairment and
its variants are often considered to be “transition
states” between normal cognitive functioning and
dementia. Thus, cognitive aging can be described as
comprising heterogeneous trajectories across domains
or by categories, including “normal,” “MCI,” and
“dementia.”
The clinical diagnosis of probable AD is made by analyz-
ing the neuropsychological profile and history of a
patient and after ruling out other potential causes of the
dementia syndrome. In clinical neuroscience, our reliance
on a taxonomic system for the characterization of age-
associated cognitive syndromes suggests, at least implic-
itly, that there is a unitary disease or pathology that
accounts for the clinical or cognitive presentation.
Indeed, pathologically, AD is defined by the presence of
of amyloid plaques and neurofibrillary tangles, which
emerge in the hippocampal formation and spread
throughout posterior and anterior cortex. However, accu-
mulating evidence indicates that, in addition to the
pathological features that define the disease, factors asso-
ciated with poor cognitive aging (in the absence of frank
dementia) may play a primary role in the pathogenesis
and progression of AD. At the top of the list of these fac-
tors are small-vessel cerebrovascular disease and its
antecedent modifiable risk factors. Epidemiological stud-
ies, for example, confirm that hypertension, diabetes,
insulin resistance, obesity/overweight, and hyperlipidemia
increase the risk of AD.
1-6
The role of neuroimaging in cognitive aging
While associative epidemiological studies play an impor-
tant role by identifying correlates of poor cognitive aging
or AD, they tell us little about directional causality or
brain mechanisms involved in pathogenesis. Over the
past three decades, the field of biomedical engineering
has infused the clinical neurosciences with powerful neu-
roimaging instruments equipped to study directly mor-
phological and functional properties of the aging brain in
vivo. Advances in the acquisition, visualization, and
analysis of neuroimaging data continue to evolve rapidly,
with ongoing development of hardware, software, and
conceptual statistical approaches that have already made
tremendous scientific contributions. Structural magnetic
resonance imaging (MRI) in particular can be used to
examine macrostructural changes—gross differences in
tissue volume that reflect volume variability, parenchy-
mal atrophy, or frank pathology (eg, large-vessel infarct,
tumor); or microstructural changes—fiber tract integrity
and pathology that can be altered due to subtle changes
in myelin-associated pathology. Several studies have
highlighted the importance of gross structural or volu-
metric changes in cognitive aging and dementia (for
example, see refs 7-11; see ref 12 for review). Small-ves-
sel cerebrovascular disease, visualized as white matter
hyperintensities (WMH), has emerged as a particularly
strong correlate of cognitive aging (for review, see ref 13)
and is the focus of our discussion here. 
Characterization and quantification of 
white matter hyperintensities
White matter hyperintensities, sometimes referred to as
leukoaraiosis or leukoencephalopathy, are areas of
increased lucency visualized on T2-weighted images.
They have enjoyed a rich, albeit capricious, history in
clinical practice and in the aging literature, at points con-
sidered incidental with little clinical significance and at
points considered a central source of cognitive, motoric,
and emotional dysfunction. Initially, WMH were
described as “unidentifiable bright objects,” confounding
radiologists as either artifactual or adventitious compan-
ions of aging. Indeed, chronological age is the strongest
correlate of WMH severity
14-16 and most older adults have
some degree of WMH burden. Figure 1 displays a typical
example of distributed WMH and Figure 2 shows exam-
ples of two elderly individuals, one with mild WMH and
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Selected abbreviations and acronyms
AD Alzheimer's disease
CAA cerebral amyloid angiopathy
FLAIR fluid attenuated inverse recovery
MCI mild cognitive impairment
MRI magnetic resonance imaging
WMH white matter hyperintensitiesone with more severe WMH reconstructed in three
dimensions. White matter hyperintensities usually appear
in the white matter confluent to the lateral ventricles (ie,
“periventricular” WMH), often projecting deep into cor-
tical white matter and grey matter nuclei (ie, “deep”
WMH), or as circumscribed punctate spheres in deep
cortical tissue. Of note, punctate WMH often appear as
isolated lesions on two-dimensional MRI axial slices, but
with three-dimensional reconstruction it often becomes
evident that they are contained within the same process
stemming off the lateral ventricles. 
Optimal characterization of the severity of WMH among
older adults has been a matter of some debate. Some
authors have argued that periventricular WMH are clin-
ically less important than deep WMH. Others have
stressed the importance of regional, or lobar, distribution
of WMH. These characteristics are reflected in many
visual rating scales, such as the Scheltens Scale,
17 which
are commonly used to evaluate the severity and distrib-
ution of WMH. Our laboratory has developed a quanti-
tative approach for regional WMH severity analysis.
Briefly, by considering the distribution of voxel intensi-
ties on individual fluid attenuated inverse recovery
(FLAIR) images, we fit Gaussian curves to each cerebral
hemisphere and derive the mean and standard deviation
for each hemisphere. White matter hyperintensity seeds
are defined as greater than or equal to 2.5 standard devi-
ations above the mean. The left and right seeds are com-
bined, and each seed is then passed into a mean inten-
sity-based region-growing algorithm. The algorithm uses
the seed voxel intensity as its starting mean and, apply-
ing a 10-point connectivity scheme (x-y plane, and 1 up
in z and 1 down in z-plane) it searches for and labels vox-
els that fall within 5% of the seed mean. Neighboring
voxels that fall within 5% are added to the image and a
new mean is created. This process continues iteratively
until all seeds have been included in the final WMH
image. The summation of the number of voxels labeled
as WMH multiplied by voxel dimensions yields the total
WMH volume. By spatially normalizing an anatomical
atlas
18 to each image, we are able to derive WMH vol-
umes in each of the major anatomical lobes, basal gan-
glia, and cerebellum. Figure 3 illustrates three orthogo-
nal views of a FLAIR image with WMH labeled and
regionally parcellated. Furthermore, through segmenta-
tion of the lateral ventricles (Figure 4), we are able to cal-
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Figure 2. Three-dimensional reconstruction of white matter hyperintensities (WMH) superimposed on a T1-weighted high resolution anatomical image.
Patient on the left has relatively mild distribution of periventricular WMH; patient on the right has more severe distribution with WMH extend-
ing into deep cortical areas. 
Figure 1. Typical distribution of white matter hyperintensities on a single
subject’s axial T2-weighted FLAIR raw image (left) and labeled
with an intensity threshold (right). FLAIR, fluid attenuated inverse
recovery.culate the distance in three dimensions of each voxel
from the ventricular wall. Thus, our quantitative process-
ing approach can be used to derive total WMH volume,
regional WMH volume, and periventricular vs deep
regional WMH volumes. 
Correlates of 
white matter hyperintensities
Despite the ubiquity of WMH among older adults, they
are a uniquely radiological phenomenon. That is, when
examining grossly the brain regions underlying WMH,
there is no obvious pigmentation abnormality. Our cur-
rent understanding of the nature, clinical importance, and
cognitive consequences of WMH has come from a num-
ber of careful clinicopathological correlates and observa-
tional studies among clinical and epidemiological sam-
ples. A prevailing view is that WMH are a surrogate
marker of small-vessel vascular disease
19 resulting from
ischemic damage due to chronic hypoperfusion. White
matter hyperintensities tend to develop in regions that
are considered “watershed” areas, which extend up to 13
mm beyond the ventricular walls.
20-22 Indeed, most of the
major risk factors for ischemia have been shown to be
associated with the severity of WMH distribution.
23-27
Further evidence for an ischemic origin comes from post-
mortem pathological examination of tissue that appears
as WMH during life. Areas most vulnerable to develop-
ment of WMH receive blood supply primarily from ven-
triculofugal vessels, which originate from the subependy-
mal arteries.
28,29 These vessels have relatively few
anastomoses and are particularly vulnerable to injury
due to systemic hypoperfusion.
29,30 Clinico-pathological
correlate studies have shown that smooth periventricu-
lar WMH are associated with subependymal gliosis and
disruption of the ependymal lining, whereas deep white
matter punctate WMH or irregularly shaped periventric-
ular WMH are associated with disruption in fibers sec-
ondary to ischemic/arteriosclerotic changes.
31,32 In gen-
eral, WMH are related to diminished pallor or
rarefaction and gliosis
33 and myelin or axonal loss.
34
By combining structural neuroimaging data with mea-
sures of cerebral blood flow, as measured by arterial spin
labeling (ASL), we showed that areas appearing as
WMH on FLAIR images had diminished blood flow rel-
ative to normal appearing white matter and grey matter.
35
The finding complements recent observations that the
spatial frequency of WMH among healthy older adults is
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Figure 4. Segmented ventricular volume (in red) superimposed on axial
and sagittal orthogonal images from high resolution T1-
weighted anatomical scan. By segmenting the ventricular sys-
tem, we are able to calculate the distance from the ventricular
walls of each white matter hyperintensity voxel. 
Figure 3. Example of regional white matter hyperintensity (WMH) quan-
tification for one subject. Upper left: raw T2-weighted FLAIR
image. Upper right and lower two: WMH labeled with
“hottest” colors indicating most hyperintense voxels. Colors cor-
respond to cerebral lobes (green: frontal, brown: parietal, dark
green: temporal, blue: occipital, mauve: cerebellum). FLAIR, fluid
attenuated inverse recoverygreater in regions with lower normative perfusion val-
ues.
36 We also showed that, among an epidemiological
cohort of nondemented older adults, WMH were associ-
ated with chronological age and vascular risk factors
37
and were most severe among adults with the highest
absolute blood pressure and blood pressure fluctuation
over a 3-year period (Brickman et al, unpublished). These
observations lend further support that diminished perfu-
sion and perhaps compromised cerebral autoregulation
increase the risk for WMH development. 
The role of white matter hyperintensities 
in cognitive aging
Consistent observations of increasing WMH severity and
variability with aging supports ongoing interest in their
clinical or cognitive correlates (see ref 13). Most inves-
tigations of the cognitive correlates of WMH burden
have been cross-sectional analyses among nondemented
older adults, and few have considered regional specificity.
Based on these studies, there is emerging evidence that
the severity or volume of WMH is one source of the cog-
nitive decline that is typical of normal aging.
38 In one of
the earlier syntheses of the cognitive correlates of WMH
in aging, a quantitative review showed that the extent of
WMH is associated particularly with poorer performance
on tasks of executive functioning and processing speed,
but not with fluid or crystallized intelligence or fine
motor functioning.
39 The results are consistent with a
more recent quantitative meta-analysis, which also
showed that the severity of WMH burden is associated
with poorer performance on speeded tasks of executive
function in both healthy elderly and in individuals with a
history of cardiovascular disease.
40
WMH may affect cognitive functioning through disrup-
tion of intracerebral connectivity, compromising efficient
neuronal communication.
41Thus, regional specificity of
the distribution of these lesions may be associated with
unique cognitive profiles. The prefrontal cortex and its
extensive cortical-cortical and cortical-subcortical con-
nectivity is thought to play a central role in executive
functioning,
10,11,42 and damage to these areas may account
for the predominant pattern of executive functioning
decline in aging. Indeed, the age-associated changes in
executive functioning appear to be partially mediated by
increased burden of WMH distributed in frontal lobe
regions
43,44 and WMH distribution in prefrontal regions
among older adults negatively impacts functional activ-
ity in the same region.
45 Despite cross-sectional observa-
tions of associations between frontal WMH and execu-
tive functioning, there has been a paucity of studies
examining the longitudinal progression of WMH and
associated changes in cognitively normal elderly. Studies
have found that increasing global WMH over a 4- or 5-
year period, but not lacunar infarcts, are associated with
worsening executive abilities and speeded abilities.
46-48
Taken together, the culmination of findings establish that
WMH are common in normal aging, progress substan-
tially, and suggest that this progression, particularly in
anterior regions, may partially account for typical age-
associated decline in executive abilities. 
The role of white matter hyperintensities 
in Alzheimer’s disease
More recently, the question of whether WMH play a
unique role in the presentation or pathogenesis of AD
has emerged. WMH are more prevalent and severe in
AD patients compared with nondemented, but demo-
graphically similar older adults.
17,49-51 Studies that have
examined regional distribution of WMH show more pos-
terior involvement, including posterior periventricular
regions and posterior corpus callosum
20,52 and increasing
caudal involvement with more severe cognitive impair-
ment.
20 Interestingly, brain regions where WMH are most
severe in AD colocalize to the distribution of AD pathol-
ogy and areas showing the greatest metabolic dysfunc-
tion in AD.
53 In our community-based study, we showed
a selective association between WMH burden and diag-
nosis of amnestic mild cognitive impairment (MCI)—
those at greatest risk for development of AD—but not
nonamnestic MCI.
54 Preliminary examination of the
regional distribution showed that WMH burden in pari-
etal lobes discriminated best among those with amnestic
MCI, non amnestic MCI, and controls, again suggesting
that a posterior distribution may be specific to or linked
pathologically to AD. 
Whether evaluation of neuroimaging data at one point
in time has prognostic value for future clinical course or
progression to AD remains an important question. Older
adults who are not demented but who have increased
WMH burden are at higher risk for the development of
AD
55-57 and MCI.
58We sought to determine whether base-
line measurement of WMH severity and global atrophy,
as a proxy of overall disease burden, predict future cog-
nitive decline among patients with AD.
59 Using a series
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strated that the degree of baseline atrophy, the severity
of WMH, and their interaction predicted the rate of cog-
nitive decline. That is, greater severity of baseline atro-
phy and greater severity of baseline WMH were associ-
ated with faster rates of cognitive decline in AD and the
interaction of the two variables suggest synergy between
cerebrovascular disease and overall disease burden.
These findings are consistent with others showing that
the presence of both elevated amounts of atrophy and
high WMH burden is more associated with AD than
either measure alone.
60,61 Results have been somewhat
mixed, however, as neither Smith and colleagues
59 nor
DeCarli and colleagues
62 found that variability in base-
line measures of total WMH burden predicted future
conversion from cognitively normal or MCI to AD. 
The association of vascular risk factors, brain perfusion
abnormalities, and increased WMH burden with AD sug-
gests that vascular disease plays an important role in the
pathogenesis of AD. Vascular disease may increase risk or
lower a clinical threshold for the expression of the disease
even in the absence of a mechanistic link or, alternatively,
may be mechanistically related. Prevailing hypotheses on
the pathogenesis of AD implicate abnormal deposition of
parenchymal Aβ protein,
63 and research shows that hav-
ing high levels of plasma Aβ42 that decrease over time
elevates risk for development of AD, presumably reflect-
ing deposition and oligomerization of Aβ peptides in
senile plaques in the brain.
64 However, recent literature
suggests that vascular deposition of Aβ, primarily com-
prising the Aβ40 species, may also be a primary patholog-
ical feature of the disease. For example, in vitro studies
show that the severity and frequency of white matter, but
not gray matter, perivascular spaces is greater in AD and
correlates with the amount of Aβ deposition in overlying
cortex and associated arteries.
65As vascular Aβmay inter-
fere with the ability of the blood vessel walls to shunt
deposited Aβ peptides through the periarterial spaces in
the brain vasculature
66-69 and white matter in AD contains
4 times more soluble Aβ than among controls,
70 it is pos-
sible that the increased WMH burden among patients
with AD, to some degree, reflects the pathological accu-
mulation of vascular Aβ. Plasma Aβ40 concentrations
have been shown to be associated with WMH burden
among patients with AD and MCI
71 and among members
of the Rotterdam cohort with the APOE-Ε4 allele.
72These
cross-sectional efforts provide evidence that increases in
circulating Aβ40 may cause white matter microvascular
damage, or, alternatively, that the accumulation of
microvascular white matter disease causes pathological
release of cerebral Aβ40 into the blood plasma.
Longitudinal studies are critical to define whether
increases in plasma Aβ40 are a biomarker of cerebrovas-
cular disease or a risk factor for the development of cere-
brovascular disease.
71
Direct examination of the association between centrally
deposited Aβ and WMH provides another approach
towards understanding a link between WMH or
microvascular disease and AD pathology, and two gen-
eral classes of studies have begun to address this issue
precisely. First, cerebral amyloid angiopathy (CAA) is
present in the vast majority of patients with AD at
autopsy. Cerebral amyloid angiopathy reflects the depo-
sition of Aβ in cerebral arterioles and is manifested as
lobar cerebral microbleeds, best visualized in vivo on T2*-
weighted gradient-echo MRI. Importantly, WMH are
more frequent in the presence of microbleeds or clinical
CAA
36,73 and those with clinical CAA show a progressive
increase in WMH, suggesting that CAA may cause pro-
gressive white matter changes.
74A recent report
75 noted
that microbleeds had a lobar distribution in 92% of
patients with AD and were predominantly distributed in
posterior regions. The presence and frequency of microb-
leeds among AD patients predicted the severity of
WMH, which was colocalized in parieto-occipital distri-
butions. Given the studies showing colocalization among
WMH, microbleeds, and the pathological distribution of
AD, it is possible that the greater posterior distribution
of WMH in AD could reflect the specific contribution of
CAA, but future studies will need to address this possi-
bility specifically. 
Second, one of the most exciting developments in neu-
roimaging has been the ability to label in vivo central
amyloid depositions using a carbon-11-labeled, lipophilic
derivative of thioflavin-T, termed “Pittsburgh Compound
B” or simply “PIB.” 
76,77 PIB can detect amyloid pathol-
ogy even among nondemented individuals
78 and has been
associated with Aβ42 levels in cerebrospinal fluid.
79 More
recently, two reports demonstrated that PIB also reliably
labels vascular deposition of Aβ and is able to discrimi-
nate patients with clinically diagnosed cerebral amyloid
angiopathy from those with AD.
80,81Thus, while the cul-
mination of studies reviewed above suggest that WMH
are purely ischemic, resulting from systemic or variable
hypoperfusion, multimodal neuroimaging, and patholog-
ical examination would suggest a more heterogeneous
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distributed in posterior cortex among individuals with
and at risk for AD. The studies highlight the potential
importance of both parenchymal and vascular β amyloid
in the pathogenesis of AD and suggest that the two are
mechanistically linked. It will be critical to extend this
line of research and determine the association between
regional distribution of WMH, cerebral microbleeds, and
PIB uptake among individuals with and without AD, and
future studies should undertake this effort among large
samples of community-based individuals. 
Current status of white matter 
hyperintensities and future directions
Structural neuroimaging studies of aging and dementia
have highlighted the importance of WMH in normal age-
associated cognitive loss and in AD. The prevailing view
of WMH is that they represent small-vessel ischemic
cerebrovascular disease secondary to perfusion abnor-
malities. Recent work implicates their involvement in the
presentation and pathogenesis of AD and points to a
potential amyloidogenic source, particularly when they
are distributed in posterior cortex. There are several con-
sistent findings regarding cerebrovascular disease in the
context of AD that have emerged, with several etiologi-
cal possibilities. First, the presence of small-vessel cere-
brovascular disease among patients with AD is the norm,
not the exception.
60 Second, patients who have coexisting
AD and small-vessel cerebrovascular disease have more
severe cognitive impairment than those having either
alone
82-84 and brain imaging markers of each seem to
interact synergistically to impact longitudinal cognitive
course.
59 Third, cerebrovascular disease and AD share
common risk factors.
87 From an etiological perspective,
AD and cerebrovascular disease may be independent,
but share common risk factors. Similarly, cerebrovascu-
lar disease may represent an independent pathology that
lowers the threshold for clinical expression of AD or con-
tributes independently to cognitive dysfunction. On the
other hand, cerebrovascular disease may be in the causal
pathway for development of AD or interact synergisti-
cally with AD pathology. These possibilities are not
mutually exclusive, but given the overlap in risk factors,
prevalence of cerebrovascular disease in AD, involve-
ment of both vascular and parenchymal forms of β amy-
loid, and interactions between the two on clinical presen-
tation, there is preliminary evidence of etiological or
mechanistic overlap. 
It is clear that future work should focus on disentangling
these etiological possibilities in order to better inform
treatment and prevention strategies. Longitudinal stud-
ies comprising community samples and incorporating
multimodal neuroimaging modalities will help establish
cause-effect relationships. For example, while associations
between WMH burden and AD have been observed, the
questions of whether the progression or accumulation of
WMH leads to AD needs to be addressed. Similarly, as
acquisition and analytic techniques continue to evolve,
investigators need to follow suit and become more pre-
cise in the questions being asked and the nature of the
neuroimaging signal under study. WMH are important
radiological correlates of cognitive aging, but most likely
represent heterogeneous pathology that requires further
elucidation through advanced imaging techniques and
combined methodological approaches.   ❏
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Neuroimágenes estructurales en la
Enfermedad de Alzheimer: ¿es importante la
hiperintensidad de la sustancia blanca? 
La disfunción cerebral objetivable que acompaña el
envejecimiento puede tener un efecto devastador
en las capacidades cognitivas e intelectuales. Un
porcentaje significativo de adultos mayores experi-
mentan una marcada declinación cognitiva que
afecta negativamente las actividades funcionales.
Esos individuos cumplen los criterios diagnósticos
clínicos para demencia, la cual se atribuye común-
mente a la Enfermedad de Alzheimer (EA). La neu-
roimagenología estructural, incluida la resonancia
magnética (RM), ha contribuido significativamente
a la comprensión de los cambios morfológicos y
aquéllos relacionados con alguna patología que
pueden estar a la base del cambio cognitivo normal
y el asociado con alguna enfermedad durante el
envejecimiento. Las hiperintensidades de la sustan-
cia blanca (HSB), que se distribuyen en parches de
hiperintensidad de señal en las secuencias poten-
ciadas en T2 están entre los hallazgos más frecuen-
tes de la neuroimagenología estructural en los
adultos mayores. En los últimos años, la HSB se ha
considerado un potente correlato radiológico de la
declinación cognitiva. Los estudios sugieren que la
HSB distribuida en las regiones cerebrales anterio-
res se relaciona con la declinación de las habilida-
des ejecutivas y es típica del envejecimiento normal;
en cambio, la HSB distribuida en regiones cerebra-
les más posteriores es común en la EA. Aunque los
estudios epidemiológicos, observacionales y pato-
lógicos sugieren que la HSB puede tener un origen
isquémico y ser causada por hipoperfusión cons-
tante o variable, ha aparecido evidencia que
sugiere que también puede reflejar depósito vascu-
lar de -amiliode, particularmente cuando está dis-
tribuida en áreas posteriores y se presenta en
pacientes con EA. Los hallazgos de la literatura des-
tacan la potencial contribución de la enfermedad
cerebro vascular de pequeño vaso a la patogéne-
sis de la EA y sugieren una interacción mecánistica,
pero se requiere a futuro de estudios longitudina-
les que utilicen varias formas de neuroimágenes
para una total comprensión del complejo papel de
la HSB en la EA. 
Neuro-imagerie anatomique dans la maladie
d’Alzheimer : impact des hyperdensités de la
substance blanche
Les dysfonctions cérébrales objectivées liées à l’âge
peuvent avoir un effet dévastateur sur les capacités
cognitives et intellectuelles. Un pourcentage signi-
ficatif d’adultes âgés subissent un déclin cognitif
brutal qui retentit défavorablement sur les activités
fonctionnelles. Ces personnes présentent des cri-
tères diagnostiques cliniques de démence, habituel-
lement rapportés à la maladie d’Alzheimer (MA). La
neuro-imagerie anatomique, dont l’imagerie par
résonance magnétique (IRM), nous a beaucoup
aidés à comprendre les modifications morpholo-
giques et pathologiques qui pourraient sous-tendre
les changements cognitifs du vieillissement normal
et pathologique. Les hyperdensités de la substance
blanche (HSB), qui se présentent sous la forme de
petites taches éparses apparaissant à l’IRM en
hypersignal en séquence pondérée en T2, sont très
fréquemment observées en neuro-imagerie anato-
mique chez les sujets âgés. Ces dernières années, les
HSB ont été reconnues comme étant des signes
radiologiques fiables du déclin cognitif. Des études
suggèrent que les HSB localisées dans la région
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